PDE4A and Alzheimer disease: Crisaborole (AN2728) is a PDE-4 inhibitor approved by the FDA and EMA for the topical treatment of mild-to-moderate AD for patients as young as 3 months of age or 2 years in the case of EMA approval (Table 6) [103,104].